BioCentury
ARTICLE | Clinical News

ArmaGen reports 52-week Phase II data for MPS I candidate

March 9, 2018 6:57 PM UTC

ArmaGen Inc. (Calabasas, Calif.) reported data from stage 2 of the Phase II portion of a Phase I/II trial in patients ages two and older with severe mucopolysaccharidosis I (MPS I, Hurler syndrome) showing that AGT-181 (HIRMAb-IDUA) stabilized several measures of neurocognitive function as measured by the neurocognitive development quotient after 52 weeks of treatment. The company said the neurocognitive development quotient is “a numerical indicator of a child's growth to maturity across a range of cognitive competencies,” and that a net decline on the endpoint would normally be expected in severe MPS I patients that have not undergone successful hematopoietic stem cell transplantation (HSCT).

ArmaGen also said AGT-181 stabilized urinary glycosaminoglycans (GAGs) levels, reduced liver and spleen volume and improved shoulder range of motion. Data were presented at the WORLDSymposium in San Diego...

BCIQ Company Profiles

ArmaGen Inc.

BCIQ Target Profiles

Insulin receptor (INSR)